Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial
Lubiprostone was well tolerated and reduced the levels of liver enzymes in patients with NAFLD and constipation. The most common adverse event was diarrhea. No life-threatening events or treatment-related deaths occurred.

Related Post